Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Mocetinostat by Bristol-Myers Squibb for Rhabdomyosarcoma: Likelihood of Approval
Mocetinostat is under clinical development by Bristol-Myers Squibb and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Data Insights
Mocetinostat by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Mocetinostat is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...